Biblio
Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients. Hemasphere. 2023;7(10):e957.
Combinatorial BCL-2 family expression in Acute Myeloid Leukemia Stem Cells predicts clinical response to Azacitidine/Venetoclax. Cancer Discov. 2023.
Fludarabine, cytarabine, and idarubicin with or without venetoclax in patients with relapsed/refractory acute myeloid leukemia. Haematologica. 2023.
Identification of Adult Patients With Classical Dyskeratosis Congenita or Cryptic Telomere Biology Disorder by Telomere Length Screening Using Age-modified Criteria. Hemasphere. 2023;7(5):e874.
Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia. Mol Cancer. 2023;22(1):196.
Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2023.
Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation. Blood. 2023.
Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panel. Am J Hematol. 2023.
Myeloid leukemia vulnerabilities embedded in long noncoding RNA locus . iScience. 2023;26(10):107844.
A new player in IDH1 mutated myeloid neoplasias. Lancet Haematol. 2023;10(1):e7-e8.
. Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease. J Hematol Oncol. 2023;16(1):96.
Using Measurable Residual Disease to Optimize Management of AML, ALL, and Chronic Myeloid Leukemia. Am Soc Clin Oncol Educ Book. 2023;43:e390010.
. Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy. Ann Hematol. 2022.
Reduced intensity hematopoietic stem cell transplantation for myelofibrosis in accelerated-phase. Blood Adv. 2022.
Resistance to targeted therapies in acute myeloid leukemia. Clin Exp Metastasis. 2022.
. Long-term survival benefit after allogeneic hematopoietic cell transplantation in chronic myelomonocytic leukemia. Biol Blood Marrow Transplant. 2020.
Allogeneic stem cell transplantation in patients with myelofibrosis harboring the MPL-mutation. Eur J Haematol. 2019.
Gemtuzumab Ozogamicin in -Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study. J Clin Oncol. 2019:JCO1901406.
In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site. Leukemia. 2019.
.